Navigation Links
Decline in Paternity Rates Following Treatment for Testicular Cancer

A recent study published in the November issue of the Journal of the National Cancer Institute, shows that paternity rates of testicular cancer patients declined after treatment, and patients treated with the higher chemotherapy dose had the lowest chance of becoming fathers. //

Germ-cell testicular cancer is the most common cancer among 20-40 year old men. Many testicular cancer patients are diagnosed at an age at which they are starting a family, and the ability to father children in the future is an important issue for approximately 60% of newly diagnosed patients.

Subfertility or infertility can be associated with the disease itself or with its treatment. Approximately half of all testicular cancer patients have defective spermatogenesis at diagnosis, even before orchiectomy.

Researchers from Norway assessed post-treatment paternity among long-term survivors of testicular cancer whose treatment had followed a modern management approach. A total of 1814 men who had been treated for unilateral testicular cancer in Norway during 1980 through 1994 were invited to participate in a national multi-center follow-up survey in 1998 through 2002.

The participants were allocated to five groups according to the treatment received after orchiectomy, including treatment at relapse (surveillance, retroperitoneal lymph node dissection, radiotherapy, low-dose chemotherapy, and high-dose chemotherapy).

Results obtained depicted that a total of 1433 men were assessable, of whom 827 were fathers at diagnosis. 554 men had attempted post-treatment conception, among whom the overall 15-year actuarial post-treatment paternity rate was 71% without the use of cryopreserved semen. This rate ranged from 48% in the high-dose chemotherapy group to 92% in the surveillance group.

Assisted reproductive technologies were used by 22% of the couples who attempted conception after treatment. Dry ejaculation, treatment group, pretreatment fa
'"/>




Page: 1 2

Related medicine news :

1. Poor health care in Russia maybe causing Decline in its Population
2. Anemia may Lead to Physical Decline
3. Exercise Can Decrease Mental Decline
4. Folic Acid Retards Mental Decline In Middle Aged Subjects
5. Breastfeeding Decline In Middle East Worries UN
6. Preventing Age-Related Mental Decline By Consuming Vitamin B
7. Drug Use On The Decline Among US Youth
8. Delhi Sees Sharp Decline In Chicken Prices
9. Global Seagrass Decline Affects Shallow-water Ecosystems
10. Decline of Suicide Rates to a Record Low, Holds Promise
11. Contraceptive Use on the Decline among the Poor
Post Your Comments:
(Date:12/4/2008)...er 4, 2008) - An Ontario study of 491 women with ...ion, 19%, were referred for genetic testing of BRC... family members are not informed of their cancer r...or at the University of Toronto,s Lawrence S. Bloo... at Women,s College Research Institute, led the nu...
(Date:12/4/2008)... Reawakening a dormant gene could ease sick... (Vocus) December 4, 2008 -- Researchers a...al.org ) and Dana-Farber Cancer Institute have ide...form of hemoglobin normally made only before birth...form sickle-cell disease and beta-thalassemia -- l...
(Date:12/4/2008)...Dec. 4 NAMC members can gain acces...desktop. Webinars feature nationally-recognized sp...ter. The next webinar will be on December 10, 200...e Audience , Do you know where your online infl..., do you know how to engage them? , This webin...
(Date:12/4/2008)... Dr. Stephen Joffe, Craig Joffe, a...Schedule 13D with the U.S.,Securities and Exchang...isclosing ownership of 11.4% of LCA-Vision, Inc. (...ed-site laser vision correction centers in 33 stat...r and former Chairman and CEO of,LCAV. Craig Jof...
Breaking Medicine News(10 mins):Health News:Few Ontario women with invasive ovarian cancer referred for genetic testing of breast cancer genes 2Health News:Turning back the Clock in Inherited Anemias 2Health News:Turning back the Clock in Inherited Anemias 3Health News:Turning back the Clock in Inherited Anemias 4Health News:New NAMC Member Service! Complimentary Webinars for NAMC Members - On Topics You Need to Know! Sign Up Today for This New and Exciting Educational Program! 2Health News:11.4% Shareholders & Former Executive Management of LCA-Vision Seek Board Representation and Executive Management Positions 2Health News:11.4% Shareholders & Former Executive Management of LCA-Vision Seek Board Representation and Executive Management Positions 3Health News:11.4% Shareholders & Former Executive Management of LCA-Vision Seek Board Representation and Executive Management Positions 4Health News:11.4% Shareholders & Former Executive Management of LCA-Vision Seek Board Representation and Executive Management Positions 5Health News:11.4% Shareholders & Former Executive Management of LCA-Vision Seek Board Representation and Executive Management Positions 6
...r Disease Control and Prevention (CDC) shows that ...ve among teenagers.// The CDC defines binge drin..." and the National Institute of Alcohol Abuse and ...attern of drinking that brings a person’s blood al...
...the US the present guidelines should be modified a...rnal of Respiratory and// Critical Care Medicine. ...fied as "high-risk,” when they have originally com...This paper has been published by American Thoracic...
...ring during the winter cold and flu season//, a vo...alth System is offering tips for preventing and tr...e of voice change that can accompany the common co... something that is quite common, and I’m sure most...
...lung function who later develop chronic cough and ... chronic obstructive pulmonary disease (COPD). The...in the first issue for January 2007 of the America... Care Medicine, published by the American Thoracic...
Other Medicine News:Health News:TB can Be Eradicated in the U.S With Modified Guidelines: Study 2Health News:Tips to Prevent and Treat Winter Laryngitis 2Health News:Cough and Phlegm Cause Fourfold Increase in COPD Incidence 2
(Date:12/3/2008)... NEWARK, Del., Dec. 3 Isogen, a c...n for sterile filling, announced it has retained a...erations to meet the global,biopharma demand for ...announced a successful first round series of capit...g line facility in Q1 2009 to,deliver on the prev...
(Date:12/2/2008)... CHICAGO, Dec. 3 Breas...he detection of cancers not found on mammograms or... today at the annual meeting of,the Radiological ...n identify the most difficult to detect breast can... Rachel F. Brem, M.D., professor of,radiology and...
(Date:12/2/2008)... BETHESDA, Md., Dec. 2 ...cal company developing novel, proprietary antibodi...utoimmune diseases, today announced that it has en...uity Financing Facility (CEFF) with Kingsbridge Ca...the terms of the agreement, Kingsbridge has commit...
(Date:12/1/2008)... SINGAPORE, Dec. 1 S*BIO Pte Ltd ...ical trial of SB1518, a potent and orally-active J...alia for patients with chronic idiopathic myelofib... evaluate the safety and tolerability of SB1518 in... 50 patients. The Phase 1 part of the study will ...
Breaking Medicine Technology:Isogen Retains Strategic Partner Sheridan Road Financial to Meet Global Biopharma Demand 2Isogen Retains Strategic Partner Sheridan Road Financial to Meet Global Biopharma Demand 3New Breast Imaging Technology Targets Hard-to-Detect Cancers 2New Breast Imaging Technology Targets Hard-to-Detect Cancers 3Micromet Expands Committed Equity Financing Facility to $75 Million 2Micromet Expands Committed Equity Financing Facility to $75 Million 3Micromet Expands Committed Equity Financing Facility to $75 Million 4Micromet Expands Committed Equity Financing Facility to $75 Million 5Micromet Expands Committed Equity Financing Facility to $75 Million 6S*BIO Advances JAK2 Inhibitor SB1518 into Phase 1/2 Clinical Trial in Australia for the Treatment of Chronic Idiopathic Myelofibrosis 2S*BIO Advances JAK2 Inhibitor SB1518 into Phase 1/2 Clinical Trial in Australia for the Treatment of Chronic Idiopathic Myelofibrosis 3Ron Greenspan DDS Creates Plan to Eliminate the Barriers to Orthodontic Treatment 23999 1Ron Greenspan DDS Creates Plan to Eliminate the Barriers to Orthodontic Treatment 23999 2AMT Starts Collaboration With St Jude Childrens Research Hospital on Gene Therapy for Hemophilia B Company Accesses Exclusive Commercial Rights to F 6542 1AMT Starts Collaboration With St Jude Childrens Research Hospital on Gene Therapy for Hemophilia B Company Accesses Exclusive Commercial Rights to F 6542 2AMT Starts Collaboration With St Jude Childrens Research Hospital on Gene Therapy for Hemophilia B Company Accesses Exclusive Commercial Rights to F 6542 3AMT Starts Collaboration With St Jude Childrens Research Hospital on Gene Therapy for Hemophilia B Company Accesses Exclusive Commercial Rights to F 6542 4Aggressive preschoolers found to have fewer friends than others 23995 1Aggressive preschoolers found to have fewer friends than others 23995 2Culture and depression 23992 1Culture and depression 23992 2
...wire/ -- Phase 3 results,from the RE-NOVATE(TM) tr...ce daily, administered for an average of 33 days, ...for an average of 33,days, in preventing venous th...total hip replacement surgery. In this trial, the,...etexilate was,similar to enoxaparin. The incidence...
...oper Antisoma plc,(LSE: ASM, US OTC: ATSMY) today ...04 in recurrent, platinum-sensitive ovarian cancer...us chemotherapy,(n=37) with patients receiving che...ollows: , * There was no advantage in median time ...ith the control arm * One-year survival,rates were...
Other Medicine Technology:Phase 3 Results for Dabigatran Etexilate, an Investigational Oral,Anticoagulant, Presented Today at the XXIst Congress of the,International Society on Thrombosis and Haemostasis 2Phase 3 Results for Dabigatran Etexilate, an Investigational Oral,Anticoagulant, Presented Today at the XXIst Congress of the,International Society on Thrombosis and Haemostasis 3Phase 3 Results for Dabigatran Etexilate, an Investigational Oral,Anticoagulant, Presented Today at the XXIst Congress of the,International Society on Thrombosis and Haemostasis 4Phase 3 Results for Dabigatran Etexilate, an Investigational Oral,Anticoagulant, Presented Today at the XXIst Congress of the,International Society on Thrombosis and Haemostasis 5Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial 2Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial 3
Each ENDOKNOT™ consists of a 42" long suture inserted into a plastic tube. The plastic tube is narrow at one end and scored on the other. The suture protrudes from the narrow end and swaged to
The ENDOLOOP consists of 18'' long ligature inserted into a plastic tube. The plastic tube is narrow at one end and scored on the other. The suture protrudes from the narrow end and is formed in a li
The ENDOLOOP consists of 18'' long ligature inserted into a plastic tube. The plastic tube is narrow at one end and scored on the other. The suture protrudes from the narrow end and is formed in a li
...201+ is the latest addition to the HemoCue glucose...new system combines the precision and accuracy of ...time and ease of use. The new pocket size analyser... date and time for up to 600 measurements. The sto...
Medicine Products: